1. Home
  2. GRTX

GRTX

Galera Therapeutics Inc.

Logo Galera Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Founded: 2012 Country:
United States
United States
Employees: N/A City: MALVERN
Market Cap: 9.0M IPO Year: 2019
Target Price: $0.35 AVG Volume (30 days): 1.7M
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.33 EPS Growth: N/A
52 Week Low/High: $0.09 - $3.59 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 398.12%

Share on Social Networks: